Gan & Lee Pharmaceuticals Presents Phase II Results of GZR18 and GZR4 at ADA Scientific Sessions
China-based Gan & Lee Pharmaceuticals (SHA: 603087) presented multiple Phase II clinical outcomes for its...
Obesity
Changshan Biochemical Receives NMPA Clearance for Albenatide in Weight Loss Trials
China’s Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) announced that it has received...
Zhongsheng Pharma’s RAY1225 Enters Phase III Trial for Obesity/Overweight Treatment
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the initiation of the multi-center, randomized,...
Medtide’s IPO Raises HKD 514 Million to Expand Global Peptide CRDMO Services
Hangzhou-based Medtide Inc., a leading Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides,...
MindRank’s MDR-001 Phase IIb Study Achieves Clinical Endpoints for Weight Loss
China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced that the multi-center, 24-week Phase IIb...
Eccogene Announces First Patient Dosing in Phase Ib Study of AZD5004/ECC5004 in China
Sino-US firm Eccogene Inc., a partner of UK major AstraZeneca (AZ, NASDAQ: AZN), announced the...
Novo Nordisk Partners with Alibaba Health to Launch Weight Management Hub”
Denmark-based Novo Nordisk (NYSE: NVO) has entered into a partnership with China’s Alibaba Health Information...
Novo Nordisk Advances Amycretin for Weight Management in Phase III Trials
Denmark-based pharmaceutical major Novo Nordisk (NYSE: NVO) announced plans to advance both subcutaneous and oral...
Innovent Biologics Initiates Phase III Trial for Mazdutide in OSA and Obesity
China-based Innovent Biologics, Inc. (HKG: 1801) announced the dosing of the first participant in China...
Lilly Launches Mounjaro Multi-Dose Pen in China for Diabetes and Weight Management
US-based Eli Lilly & Co. (NYSE: LLY) announced the launch of Mounjaro (tirzepatide multi-dose prefilled...
Novo Nordisk China Restructures to Form New Obesity and Diabetes Department
Danish pharmaceutical giant Novo Nordisk’s (NYSE: NVO) China unit announced an organizational restructuring, merging its...
Innogen Pharma Resubmits Hong Kong IPO Application With Promising Diabetes Drug
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. has resubmitted its application for a main board...
Salubris Pharmaceuticals’ Allisartan-Indapamide Hybrid Wins NMPA Approval
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, announced that it has...
Eli Lilly Partners with Camurus on Long-Acting Cardiovascular and Metabolic Health Products
US-based Eli Lilly & Co. (NYSE: LLY) entered into a collaboration and licensing agreement with...
BioAge Labs Partners with JiKang for APJ Agonist Nanobody License
US-based biotech BioAge Labs, Inc. announced an option agreement with China’s JiKang Therapeutics, potentially securing...
Hansoh Pharmaceutical Partners with Regeneron for HS-20094 Global Rights
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with Regeneron Pharmaceuticals...
Guangdong Zhongsheng Wins Peking University People’s Hospital Nod for RAY1225 Phase III Trials
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...
Novo Nordisk’s Wegovy Demonstrates Early Cardioprotective Effects in SELECT Trial
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced groundbreaking secondary analysis results from...
Ascletis Pharma Initiates ASC47-103 Study in US for Obesity Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) announced the first subject dosing of the ASC47-103 study...
Suzhou’s PegBio Launches Hong Kong IPO Amid Pipeline Progress
Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO,...